It is unknown whether home blood pressure (BP) variability reduction is associated with target organ damage (TOD) protection independently of home mean BP reduction. We enrolled 310 hypertensive patients whose systolic BP (SBP) at home was over 135 mm Hg. The subjects measured their BP in the morning and evening for 7 days. In addition, we measured urinary albumin excretion (UAE) as a marker of TOD before and after 6 months of candesartan treatment ( þ thiazidediuretics). At baseline, UAE was associated with average home SBP (r ¼ 0.24, Po0.001), the s.d. of home SBP (r ¼ 0.15, P ¼ 0.011), and the maximum home SBP (r ¼ 0.27, Po0.001). During the intervention, significant reductions were found in average home SBP (146 ± 13 vs. 132 ± 12 mm Hg, Po0.001), s.d. of home SBP (12.9 ± 4.8 vs. 11.8 ± 4.4 mm Hg, Po0.001), and maximum home SBP (172.5±18.0 vs. 155.9±17.5 mm Hg, Po0.001). UAE levels were significantly reduced after 6months of therapy compared with baseline (18.9 vs. 12.1 mg g À1 Cre, Po0.001). In multiple regression analysis, the treatment-induced reduction in UAE was significantly associated with that of average home BP (P ¼ 0. Keywords: day-to-day blood pressure variability; home blood pressure; urinary albumin excretion INTRODUCTION Many studies have focused on the association between blood pressure (BP) variability (BPV) and target organ damage (TOD) or cardiovascular prognosis. 1-5 Studies based on ambulatory BP monitoring have provided evidence that BPV over 24 h was associated with the severity of organ damage and the rate of cardiovascular events. 6,7 Recently, in conventional office BP measurements, increased visit-tovisit variability, calculated as the s.d. of the mean of repeated recordings and maximum systolic BP (SBP) over a certain period, has been reported to indicate increased cardiovascular risk. 5 We have reported that not only office BPV but also day-to-day BPV evaluated by home BP (HBP) monitoring (HBPM) is associated with TOD (that is, cardiac hypertrophy and carotid artery remodeling) independently of average office or HBP levels. 8,9 Moreover, Kikuya et al. 4 reported that the increased day-to-day BPV, calculated as the s.d. of HBP, was associated with cardiovascular mortality in a community-dwelling population. However, it is not clear whether home BPV itself, beyond the mean HBP level, can contribute directly to the development of TOD. The treatment-induced change in TODs assessed by cardiovascular biomarkers, such as the level of urinary albumin excretion (UAE), is associated with prognosis; 10-12 therefore,